Renal Non-Clear Cell Carcinoma — Trials

Renal Non-Clear Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

71 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 37
Recruiting: 15
Ph III recruiting: 0
Growth YoY: —
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (4)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03177239	Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)(UNISoN)	unknown	Phase 2	85	Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER	1	Feb 16, 2022	clinicaltrials

Data updated 23 days agoSource updated Feb 16, 2022source: clinicaltrials